Reproductive-age women with SLE are prone to be impacted by endometriosis. This study analyzes the relationship between HCQ and endometriosis patients with SLE in order to determine whether HCQ is effective for treating the latter.
Study Finds Blood Levels of Plaquenil may be Important Indicator of Eye Disease Risk
Research Supports Measuring Blood for Hydroxychloroquine Levels
Hydroxychloroquine (Plaquenil®) is the most prescribed medication in the treatment of lupus and has numerous benefits including prevention of flares, prolonged survival, and other positive outcomes. Medication non-adherence is reported in up to 80% of people with lupus and is associated with reduced health outcomes.
200 mg Limit to Hydroxychloroquine Tablets Challenging for SLE Patients
One-quarter of systemic lupus erythematosus patients in the U.S. taking hydroxychloroquine tablets daily are exceeding the recommended doses for this treatment, and up to one-third of those on alternate-day treatment are forgetting or mixing up their medication, a study reports.
The problem, researchers say, is that only 200 mg tablets exist – and many patients are prescribed a 300 mg dose. New dosage forms are needed to ensure proper treatment, researchers recommend.